Send Message
801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsOral Medications

Sirolimus Capsules 0.5mg, 1.0mg Oral Medications

Sirolimus Capsules 0.5mg, 1.0mg Oral Medications

  • Sirolimus Capsules 0.5mg, 1.0mg Oral Medications
Sirolimus Capsules 0.5mg, 1.0mg Oral Medications
Product Details:
Place of Origin: China
Brand Name: Newlystar
Certification: GMP
Model Number: 0.5mg, 1.0mg
Payment & Shipping Terms:
Minimum Order Quantity: 500, 000 capsules
Price: Negotiation
Packaging Details: 10’s/blister
Delivery Time: 45days
Payment Terms: L/C, T/T
Supply Ability: One million pills per day
Contact Now
Detailed Product Description
Product: Sirolimus Capsules Specification: 0.5mg, 1.0mg
Standard: In - House Packing: 10’s/blister
High Light:

oral medicine

,

oral preparation

Sirolimus Capsules 0.5mg, 1.0mg Oral Medications

 

Product : Sirolimus Capsules

Specification : 0.5mg, 1.0mg

Standard : In - house

Packing : 10’s/blister

 

Description :

A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to immunophilins. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.

 

Indication

For the prophylaxis of organ rejection in patients receiving renal transplants.

 

Pharmacodynamics

Sirolimus, a macrocyclic lactone produced by Streptomyces hygroscopicus, is an immunosuppressive agent indicated for the prophylaxis of organ rejection in patients receiving renal transplants. It is recommended that sirolimus be used in a regimen with cyclosporine and corticosteroids.

 

Mechanism of action

Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.

Contact Details
Newlystar (Ningbo) Medtech Co.,Ltd.

Contact Person: Mr. Luke Liu

Tel: 86--57487019333

Fax: 86-574-8701-9298

Send your inquiry directly to us (0 / 3000)

Other Products